Population-based meta-analysis of furosemide pharmacokinetics

被引:20
作者
Van Wart, Scott A. [1 ,2 ]
Shoaf, Susan E. [3 ]
Mallikaarjun, Suresh [3 ]
Mager, Donald E. [2 ]
机构
[1] Inst Clin Pharmacodynam, Latham, NY 12110 USA
[2] SUNY Buffalo, Dept Pharmaceut Sci, Buffalo, NY 14260 USA
[3] Otsuka Pharmaceut Dev & Commercializat Inc, Rockville, MD USA
关键词
heart failure; population pharmacokinetics; furosemide; cirrhosis; CONGESTIVE-HEART-FAILURE; DRUG INPUT RATE; LOOP DIURETICS; PHARMACODYNAMIC ANALYSIS; QUANTIFICATION LIMIT; HEALTHY-VOLUNTEERS; INDIVIDUAL-LEVEL; AGGREGATE DATA; HANDLING DATA; FRUSEMIDE;
D O I
10.1002/bdd.1874
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Furosemide is a loop diuretic frequently used to treat fluid overload conditions such as hepatic cirrhosis and congestive heart failure (CHF). A population-based meta-analysis approach in NONMEM (R) was used to develop a PK model characterizing the time-course of furosemide in plasma and excretion into the urine for healthy subjects and fluid overload patients. Furosemide PK data from healthy subjects receiving 80 mg of oral furosemide were supplemented with additional individual and aggregate plasma concentration and urinary excretion versus time data from the literature after intravenous (i.v.) or oral furosemide administration (10-500 mg) to healthy subjects or fluid overload patients. A three-compartment model with zero-order input following i.v. administration (or first-order absorption using a Weibull function after oral administration) and first-order elimination best described furosemide PK. A covariate analysis identified creatinine clearance (CLCR) as a statistically significant predictor of renal clearance (CLR), with a population mean CLR of 4.67, 3.11, 1.95 and 1.17 l/h for a subject with normal renal function (CLCR = 120 ml/min) or mild (CLCR = 80 ml/min), moderate (CLCR = 50 ml/min) or severe (CLCR = 30 ml/min) renal impairment. Oral bioavailability was 59.1% and non-renal clearance was 2.02 l/h. A PC-VPC and other model diagnostics demonstrated that the population PK model can reasonably predict the rate of urinary furosemide excretion over time using dosing history and commonly available demographic data, allowing for convenient assessment of PK-PD relationships for furosemide when given alone or in combination with other agents used to treat fluid overload conditions. Copyright (c) 2013 John Wiley & Sons, Ltd.
引用
收藏
页码:119 / 133
页数:15
相关论文
共 50 条
  • [41] Hypertonic saline with furosemide for the treatment of acute congestive heart failure: A systematic review and meta-analysis
    Gandhi, Sumeet
    Mosleh, Wassim
    Myers, Robert B. H.
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 173 (02) : 139 - 145
  • [42] Comparative effects of furosemide and other diuretics in the treatment of heart failure: a systematic review and combined meta-analysis of randomized controlled trials
    Peter Samuel Eid
    Doaa Alaa Ibrahim
    Ahmad Helmy Zayan
    Manal Mahmoud Abd Elrahman
    Mostafa Ahmed Abdo Shehata
    Hend Kandil
    Mahmoud Ahmed Abouibrahim
    Luc Minh Duy
    Ashraf Shinkar
    Muhammed Khaled Elfaituri
    Le Huu Nhat Minh
    Mostafa Mahmoud Fahmy
    Dao Ngoc Hien Tam
    Nguyen Lam Vuong
    Jaffer Shah
    Van Buu Dan Do
    Kenji Hirayama
    Nguyen Tien Huy
    [J]. Heart Failure Reviews, 2021, 26 : 127 - 136
  • [43] Comparative effects of furosemide and other diuretics in the treatment of heart failure: a systematic review and combined meta-analysis of randomized controlled trials
    Eid, Peter Samuel
    Ibrahim, Doaa Alaa
    Zayan, Ahmad Helmy
    Abd Elrahman, Manal Mahmoud
    Shehata, Mostafa Ahmed Abdo
    Kandil, Hend
    Abouibrahim, Mahmoud Ahmed
    Luc Minh Duy
    Shinkar, Ashraf
    Elfaituri, Muhammed Khaled
    Le Huu Nhat Minh
    Fahmy, Mostafa Mahmoud
    Dao Ngoc Hien Tam
    Nguyen Lam Vuong
    Shah, Jaffer
    Van Buu Dan Do
    Hirayama, Kenji
    Nguyen Tien Huy
    [J]. HEART FAILURE REVIEWS, 2021, 26 (01) : 127 - 136
  • [44] Intermittent furosemide administration in patients with or at risk for acute kidney injury: Meta-analysis of randomized trials
    Bove, Tiziana
    Belletti, Alessandro
    Putzu, Alessandro
    Pappacena, Simone
    Denaro, Giuseppe
    Landoni, Giovanni
    Bagshaw, Sean M.
    Zangrillo, Alberto
    [J]. PLOS ONE, 2018, 13 (04):
  • [45] Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis
    Sutjandra, Liviawati
    Rodriguez, Rachelle D.
    Doshi, Sameer
    Ma, Mark
    Peterson, Mark C.
    Jang, Graham R.
    Chow, Andrew T.
    Jose Perez-Ruixo, Juan
    [J]. CLINICAL PHARMACOKINETICS, 2011, 50 (12) : 793 - 807
  • [46] Continuous versus intermittent administration of furosemide in acute decompensated heart failure: a systematic review and meta-analysis
    Akira Kuriyama
    Seigo Urushidani
    [J]. Heart Failure Reviews, 2019, 24 : 31 - 39
  • [47] Comments on hypertonic saline with furosemide for the treatment of acute congestive heart failure: A systematic review and meta-analysis
    Niu, Xiaowei
    Yang, Cuiling
    Yao, Yali
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 176 (01) : 288 - 288
  • [48] Continuous versus intermittent administration of furosemide in acute decompensated heart failure: a systematic review and meta-analysis
    Kuriyama, Akira
    Urushidani, Seigo
    [J]. HEART FAILURE REVIEWS, 2019, 24 (01) : 31 - 39
  • [49] A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design
    Davda, Jasmine P.
    Dodds, Michael G.
    Gibbs, Megan A.
    Wisdom, Wendy
    Gibbs, John P.
    [J]. MABS, 2014, 6 (04) : 1094 - 1102
  • [50] The Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid: Systematic Review and Meta-analysis
    Takuathung, Mingkwan Na
    Sakuludomkan, Wannachai
    Koonrungsesomboon, Nut
    [J]. CLINICAL PHARMACOKINETICS, 2021, 60 (10) : 1291 - 1302